All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
10 warning events since 2017; the latest 2025-08-28.
From the record
Imunon, Inc.'s filings since 2017 show 10 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 9 times, the latest 2025-08-28); an auditor change (8-K item 4.01, the latest 2017-09-21) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+0% a year over 6 filed years; profitable in 0 of 6.
From the record
Imunon, Inc.'s 6 filed years say what it did: revenue went from $500 thousand in fiscal 2017 to $500 thousand in fiscal 2022, up 0% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 0 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 3.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Imunon, Inc.'s shareholder treatment is put at 3.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 33% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -205%: lost 205¢ per shareholder dollar. Leverage 43%: owes 43¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Imunon, Inc. lost about 205 cents for every dollar of shareholders' money. Leverage: it owed about 43 cents per dollar of assets, and net share issuance: its share count grew 93.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 22% of 315 in its family; net margin -7179.6%.
From the record
Imunon, Inc.'s standing among 315 graded names in its industry family: revenue of $500 thousand in fiscal 2022 ranks in the bottom 16% by size; a net margin of -7179.6% ranks in the bottom 12%; revenue growth of 0% a year over the last 3 filed years ranks in the bottom 38% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 27% of 315 in its family for leadership; chief executive since 2024.
From the record
Imunon, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Lindborg, Stacy (President and CEO, as filed), filing under that title since 2024-05-14, 2.5 years (bottom 28% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 5.4 years (bottom 45%); 14 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 8%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 7.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Imunon, Inc.'s room to expand is put at 7.8 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 22% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
bottom 47% of 306 in its family for growth drivers.
From the record
Imunon, Inc.'s growth drivers, from the filed years to fiscal 2022: revenue grew 0% a year over the last three filed years against 0% over all 6, speeding up (top 40% of its family); the newest year grew 0% (bottom 38%); research spending grew -12.8% a year (bottom 27%); capital spending grew 1.6% a year (top 37%) (its annual reports). Imunon, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 27% of 233 in its family for expectations against reality.
From the record
Imunon, Inc.'s newest year against its own record: revenue of $500 thousand in fiscal 2022 came in 0% above the $500 thousand its prior three years' pace pointed to (top 46% of its family); net income of $36 million against a prior three-year average of $20 million (bottom 17%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 9%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made